Cerebras Opened at $350 -- Nearly Double Its IPO Price -- Then Pulled Back 20% the Next Day. Is Cerebras Stock a Buy or a Trap?

Cerebras Systems has fallen sharply after its May 14 IPO, with shares closing at $201 on June 5, more than 42% below the $350 opening price. The article highlights the risks of chasing IPO momentum, despite the company’s AI-focused chips, $20 billion OpenAI contract, and revenue growth from over $24 million in 2022 to $510 million in 2025. The piece is essentially a cautionary take on valuation, customer concentration, and loss history rather than a fresh operating update.

Analysis

The post-IPO drawdown is less about fundamentals deteriorating in real time and more about positioning air-pockets: when a deal is priced through the range and opens with a large first-day gap, the marginal holder is often momentum-sensitive, not long-duration capital. That creates a fragile shareholder base that can unwind over days to weeks once incremental buying disappears, especially in a name with a small float and a story stock tape.

The more important second-order issue is competitive signaling. A hardware architecture that can win headline benchmarks is useful for narrative, but enterprise and hyperscaler buyers care about deployment friction, software maturity, and procurement redundancy. If the installed base remains concentrated, the company may have to subsidize adoption longer than bulls expect, which compresses near-term gross margin leverage even if revenue growth stays strong over the next 2-4 quarters.

The article’s skepticism is directionally right, but the stock may already be discounting a lot of the obvious risks. The contrarian setup is that any incremental proof of diversification away from one or two anchor customers can force a violent re-rating because the market is currently treating concentration as an existential issue. Conversely, a single missed growth milestone or delayed large-order conversion would likely trigger another sharp de-rate within one earnings cycle.

For the ecosystem, the most durable beneficiary is not necessarily the direct AI-chip peer set but the incumbent platforms that own the software stack and distribution. High-profile volatility in differentiated ASIC stories can actually reinforce the premium on NVDA, AMZN, and META as lower-execution-risk exposure to AI capex, while leaving room for a secondary-market short thesis in companies whose valuation depends on scarcity rather than broad adoption.

Key Decisions for Investors

• Avoid initiating a fresh long in CBRS for the next 1-2 quarters; wait for either customer diversification evidence or a post-lockup reset. Risk/reward is poor here because downside can remain air-pocketed while upside needs a clean fundamental catalyst.
• If tactically bearish, use a 1-3 month put spread on CBRS rather than outright shorting the stock. That captures another 15-25% de-rating if growth expectations normalize, while limiting squeeze risk in a thin float name.
• Prefer long NVDA over CBRS on a 3-6 month horizon as the cleaner AI capex beneficiary. NVDA has better software lock-in and lower execution variance, so multiple compression risk is meaningfully lower even if the AI spend cycle cools.
• Use any CBRS rebound into strength as a short-entry window only if volume fades and the stock fails to reclaim post-IPO support. That setup offers attractive asymmetry because retail-driven momentum tends to exhaust quickly after initial lock-up enthusiasm fades.
• For broader AI exposure, add AMZN/META on weakness rather than chasing newer hardware stories. Their direct monetization path is more visible, making them better risk-adjusted ways to express AI spending growth over the next 6-12 months.